Design, Synthesis and SAR Analysis of Novel Potent and Selective Small Molecule Antagonists of NPBWR1 (GPR7)
Overview
Authors
Affiliations
Novel small molecule antagonists of NPBWR1 (GPR7) are herein reported. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 5-chloro-4-(4-methoxyphenoxy)-2-(p-tolyl)pyridazin-3(2H)-one as a NPBWR1 hit antagonist with micromolar activity. Design, synthesis and structure-activity relationships study of the HTS-derived hit led to the identification of 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one lead molecule with submicromolar antagonist activity at the target receptor and high selectivity against a panel of therapeutically relevant off-target proteins. This lead molecule may provide a pharmacological tool to clarify the molecular basis of the in vivo physiological function and therapeutic utility of NPBWR1 in diverse disease areas including inflammatory pain and eating disorders.
Liu M, Bu G, Wan Y, Zhang J, Mo C, Li J Endocrinology. 2022; 163(7).
PMID: 35583189 PMC: 9170129. DOI: 10.1210/endocr/bqac073.
Nguyen T, Decker A, Snyder R, Tonetti E, Gamage T, Zhang Y Eur J Med Chem. 2022; 231:114149.
PMID: 35101647 PMC: 8891040. DOI: 10.1016/j.ejmech.2022.114149.
SAR analysis of novel non-peptidic NPBWR1 (GPR7) antagonists.
Guerrero M, Urbano M, Schaeffer M, Brown S, Rosen H, Roberts E Bioorg Med Chem Lett. 2013; 23(3):614-9.
PMID: 23287738 PMC: 3621982. DOI: 10.1016/j.bmcl.2012.12.030.